Novartis, Roche Face $251M in Collusion Fines

Italian antitrust authorities have fined Novartis and Roche Holdings a total of $250 million for allegedly colluding to prevent the use of Roche’s Avastin cancer drug as a treatment for eye disease, in favor of a more expensive drug.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news